Tumor Regression and Allograft Rejection after Administration of Anti-PD-1.

Mednet Member

Medical Oncology · Albert Einstein College of Medicine at Montefiore Medical Center

This highly challenging question addresses a very important general issue in the context of a unique patient case. How far can we push the boundaries of using checkpoint inhibitors in understudied patient populations at significantly increased risk from adverse events? Or in different words, how muc...